EYESW (Second Sight Medical Products) ROC %: -135.29% (As of Jun. 2022)


What is Second Sight Medical Products ROC %?

Second Sight Medical Products EYESW ROC % is -135.29% as of Jun. 2022. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Second Sight Medical Products's annualized return on capital (ROC %) for the quarter that ended in Jun. 2022 was -135.29%.

As of today (2026-06-29), Second Sight Medical Products's WACC % is 22.09%. Second Sight Medical Products's ROC % is -201.17% (calculated using TTM income statement data). Second Sight Medical Products earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Second Sight Medical Products  (NAS:EYESW) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Second Sight Medical Products's WACC % is 22.09%. Second Sight Medical Products's ROC % is -201.17% (calculated using TTM income statement data). Second Sight Medical Products earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Second Sight Medical Products ROC % Related Terms

Second Sight Medical Products ROC % Historical Data

* Premium members only.

The historical data trend for Second Sight Medical Products's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Second Sight Medical Products ROC % Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -782.95 -875.47 -573.08 -271.74 -461.77

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -379.90 -688.58 -368.46 -171.57 -135.29

Second Sight Medical Products ROC % Calculation

Second Sight Medical Products's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-8.933 * ( 1 - 0% )/( (2.564 + 1.305)/ 2 )
=-8.933/1.9345
=-461.77 %

where

Invested Capital(A: Dec. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.46 - 2.759 - ( 3.177 - max(0, 5.132 - 4.269+3.177))
=2.564

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=70.879 - 1.529 - ( 69.593 - max(0, 2.462 - 70.507+69.593))
=1.305

Second Sight Medical Products's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2022 is calculated as:

ROC % (Q: Jun. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2022 ) + Invested Capital (Q: Jun. 2022 ))/ count )
=-12.516 * ( 1 - 0% )/( (9.028 + 9.474)/ 2 )
=-12.516/9.251
=-135.29 %

where

Invested Capital(Q: Mar. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=68.538 - 1.678 - ( 59.599 - max(0, 2.385 - 60.217+59.599))
=9.028

Invested Capital(Q: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=65.649 - 1.377 - ( 56.377 - max(0, 2.591 - 57.389+56.377))
=9.474

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -135.29% mean?
Second Sight Medical Products (EYESW) has a ROC % of -135.29% as of Jun. 2022. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Second Sight Medical Products and its competitors.
Is Second Sight Medical Products' ROC % too high?
Second Sight Medical Products' current ROC % is -135.29%.
How does Second Sight Medical Products' ROC % compare to SONX and LUCD?
Second Sight Medical Products' ROC % of -135.29% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.25, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Second Sight Medical Products and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Second Sight Medical Products's current ROC % is -135.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current ROC % of -135.29%. The current ROC % is -135.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current ROC % is -135.29% as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Second Sight Medical Products Business Description

Address 13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.